Li Jin, Liang Yu-Bo, Wang Qing-Bo, Li Yu-Kai, Chen Xing-Ming, Luo Wan-Ling, Lakang Yawhan, Yang Zi-Sheng, Wang Yan, Li Zhi-Wei, Ke Yang
Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Kunming Medical University, Kunming, China.
Department of Pathology, The Second Affiliated Hospital, Kunming Medical University, Kunming, China.
Front Immunol. 2025 Jan 7;15:1519999. doi: 10.3389/fimmu.2024.1519999. eCollection 2024.
This study aimed to investigate whether tumor-associated lymphatic vessel density (LVD) could predict the survival of patients with hepato-biliary-pancreatic (HBP) cancers after radical resection.
A systematic search was conducted using PubMed, Embase, and Cochrane Library from the inception to July 31, 2024 for literature that reported the role of LVD in overall survival (OS) and recurrence-free survival (RFS) of patients with HBP cancers after radical resection.
Ten studies with 761 patients were included for the meta-analysis. The results indicated that a higher level of LVD was associated with worse OS (hazard ratio, HR = 2.87, 95% CI 1.63 to 5.04) and worse RFS (HR = 3.18, 95% CI 1.41 to 7.17) in HBP cancers. Subgroup analysis based on pathological types revealed that a higher level of LVD was significantly related to worse OS in hepatocellular carcinoma (HCC) (HR = 2.35, 95% CI 1.16 to 4.78), cholangiocarcinoma (HR = 4.65, 95% CI 1.70 to 12.70), and gallbladder cancer patients (HR = 4.64, 95% CI 1.37 to 15.71). The levels of LVD were not significantly associated with OS in pancreatic adenocarcinoma patients after radical resection (HR = 1.08, 95% CI 0.61 to 1.89). Similarly, a higher level of LVD was significantly associated with worse RFS in HCC (HR = 1.92, 95% CI 1.01 to 3.65) and cholangiocarcinoma patients (HR = 4.54, 95% CI 2.10 to 9.83).
A higher level of LVD was a biomarker for the prediction of worse OS and RFS in patients with hepatobiliary cancers after radical resection.
https://www.crd.york.ac.uk/prospero/, identifier CRD42024571167.
本研究旨在探讨肿瘤相关淋巴管密度（LVD）是否可预测肝胆胰（HBP）癌患者根治性切除术后的生存情况。
从数据库建库至2024年7月31日，使用PubMed、Embase和Cochrane图书馆进行系统检索，以查找报告LVD在HBP癌患者根治性切除术后总生存期（OS）和无复发生存期（RFS）中作用的文献。
纳入10项研究共761例患者进行荟萃分析。结果表明，HBP癌中较高水平的LVD与较差的OS（风险比，HR = 2.87，95%CI 1.63至5.04）和较差的RFS（HR = 3.18，95%CI 1.41至7.17）相关。基于病理类型的亚组分析显示，较高水平的LVD与肝细胞癌（HCC）（HR = 2.35，95%CI 1.16至4.78）、胆管癌（HR = 4.65，95%CI 1.70至12.70）和胆囊癌患者（HR = 4.64，95%CI 1.37至15.71）较差的OS显著相关。根治性切除术后胰腺腺癌患者的LVD水平与OS无显著相关性（HR = 1.08，95%CI 0.61至1.89）。同样，较高水平的LVD与HCC（HR = 1.92，95%CI 1.01至3.65）和胆管癌患者（HR = 4.54，9%CI 2.10至9.83）较差的RFS显著相关。
较高水平的LVD是预测肝胆癌患者根治性切除术后OS和RFS较差的生物标志物。
